<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TOPOTECAN HYDROCHLORIDE- topotecan hydrochloride injection, powder, lyophilized, for solution </strong><br>Actavis Pharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use TOPOTECAN HYDROCHLORIDE FOR INJECTION safely and effectively. See full prescribing information for TOPOTECAN HYDROCHLORIDE FOR INJECTION.<br><br></span><span class="Bold">TOPOTECAN hydrochloride for injection, for intravenous use<br></span><span class="Bold">Initial U.S. Approval: 1996</span>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: BONE MARROW SUPPRESSION</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning. </span></span></h1>
<p class="Highlighta"><span class="Bold">Topotecan hydrochloride can cause severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Administer only to patients with baseline neutrophil counts greater than or equal to 1,500 cells/mm<span class="Sup">3</span> and platelet count greater than or equal to 100,000/mm<span class="Sup">3</span>. Monitor blood cell counts. (<a href="#LINK_20e21abb-c512-489c-bc9b-95fe02451696">5.1</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Contraindications, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone Marrow Depression</span>, removed (<a href="#LINK_c1882ccd-7e14-4d4d-bd57-138b2a4eda4a">4)</a>            06/2015 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: BONE MARROW SUPPRESSION</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning. </span></span></h1>
<p class="Highlighta"><span class="Bold">Topotecan hydrochloride can cause severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Administer only to patients with baseline neutrophil counts greater than or equal to 1,500 cells/mm<span class="Sup">3</span> and platelet count greater than or equal to 100,000/mm<span class="Sup">3</span>. Monitor blood cell counts. (<a href="#LINK_20e21abb-c512-489c-bc9b-95fe02451696">5.1</a>)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Topotecan Hydrochloride for Injection is a topoisomerase inhibitor indicated for: </p>
<ul class="Disc">
<li>metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy. (<a href="#LINK_bfd113e9-0659-4f48-b274-ff77df4fa430">1.1</a>)</li>
<li>small cell lung cancer platinum-sensitive disease in patients who progressed after first-line chemotherapy. (<a href="#LINK_44eb6e57-e6a7-4960-99c9-546ed4954357">1.2</a>)</li>
<li>combination therapy with cisplatin for Stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment. (<a href="#LINK_d376f9c7-c134-4c4e-a130-af6e383f78bb">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Ovarian cancer and small cell lung cancer: 1.5 mg/m<span class="Sup">2</span> by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course. (<a href="#LINK_ee81b4f7-236f-473f-87d5-63f4135f911a">2.1</a>, <a href="#LINK_1411748f-e375-4bff-90a4-531b846025ed">2.2</a>)</li>
<li>Cervical cancer: 0.75 mg/m<span class="Sup">2</span> by intravenous infusion over 30 minutes on Days 1, 2, and 3 repeated every 21 days in combination with cisplatin 50 mg/m<span class="Sup">2</span> on Day 1. (<a href="#LINK_5b2223d4-4c77-41ba-8cc1-3d21da037a31">2.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Dose reduce Topotecan Hydrochloride for Injection in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (20 to 39 mL/min). (<a href="#LINK_d3839148-8041-40d0-ba5c-173ee2c8997e">2.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">4 mg (free base) lyophilized powder in single-dose vial. (<a href="#LINK_36ea209c-740f-4f89-b0b9-68929350564b">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>History of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to topotecan.(<a href="#LINK_c1882ccd-7e14-4d4d-bd57-138b2a4eda4a">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>Bone marrow suppression: Administer topotecan hydrochloride only to patients with adequate bone marrow reserves. Monitor peripheral blood counts and adjust the dose as needed. (<a href="#LINK_d3839148-8041-40d0-ba5c-173ee2c8997e">2.4</a>, <a href="#LINK_20e21abb-c512-489c-bc9b-95fe02451696">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">Neutropenic enterocolitis</span>: Fatal <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">typhlitis</span> can occur. (<a href="#LINK_f5f6744b-b23c-4a70-8004-d2c2ff20ff2a">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span> (ILD): Fatal cases have occurred. Permanently discontinue for confirmed ILD. (<a href="#LINK_e5f4ecba-3f6d-41c8-8f53-789b80897646">5.3</a>)</li>
<li>Embryofetal toxicity: Can cause fetal harm. Advise women of potential risk to the fetus. (<a href="#LINK_cfb4674a-20f9-4bbf-b29c-0a5a22fa13be">5.4</a>, <a href="#LINK_a46c1483-2803-41b1-8494-ffdf17738e9b">8.1</a>, <a href="#LINK_7a632878-0c0d-4590-9ec2-230389fd6bc0">8.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and tissue injury: Severe cases have been reported. If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occurs, immediately stop administration and institute recommended management procedures. (<a href="#LINK_5d7af648-a58d-4392-a546-13309d9f1c0f">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Ovarian cancer: </p>
<ul class="Disc"><li>The most common hematologic adverse reactions were: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (Grade 4: 80%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (Grade 3/4: 41%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (Grade 4: 27%), and <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (23%). (<a href="#LINK_0a319ebb-e955-49ba-a475-6321c840af8d">6.1</a>)</li></ul>
<ul class="Disc"><li>The most common (greater than 5%) non-hematologic adverse reactions (all grades) were: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. (<a href="#LINK_0a319ebb-e955-49ba-a475-6321c840af8d">6.1</a>)</li></ul>
<p class="Highlighta">Small cell lung cancer: </p>
<ul class="Disc">
<li>The most common hematologic adverse reactions were: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (Grade 4: 70%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (Grade 3/4: 42%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (Grade 4: 29%), and <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (28%).</li>
<li>The most common (greater than 5%) non-hematologic adverse reactions (all grades) were: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</li>
</ul>
<p class="Highlighta">Cervical cancer (topotecan hydrochloride plus cisplatin): </p>
<ul class="Disc"><li>The most common hematologic adverse reactions were: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (Grade 3/4: 74%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (Grade 3/4: 40%), and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (Grade 3/4: 33%). (<a href="#LINK_0a319ebb-e955-49ba-a475-6321c840af8d">6.1</a>)</li></ul>
<p class="Highlighta">The most common (greater than 25% and greater than or equal to 2% more than cisplatin alone) non-hematologic adverse reactions (all grades) were: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>/<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>. (<a href="#LINK_0a319ebb-e955-49ba-a475-6321c840af8d">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-432-8534 or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk"><li>Do not initiate G-CSF until 24 hours after completion of treatment with Topotecan Hydrochloride for Injection. Concomitant administration can prolong duration of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. (<a href="#LINK_fa555614-b55c-4c26-bafa-ff55a1fdb777">7</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk"><li>Lactation: Discontinue breastfeeding. (<a href="#LINK_bdb06d87-53fd-4b79-8a37-749e9d7efd64">8.2</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold"> WARNING: BONE MARROW SUPPRESSION 
</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1  INDICATIONS AND USAGE 
</span></a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Ovarian Cancer

<span class="Bold">​</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Small Cell Lung Cancer</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Cervical Cancer</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Ovarian Cancer</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Small Cell Lung Cancer</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Cervical Cancer</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Modifications</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Preparation and
Intravenous Administration</a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3  DOSAGE FORMS AND STRENGTHS 
</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4  CONTRAINDICATIONS 
</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5  WARNINGS AND PRECAUTIONS 
</span></a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Bone Marrow Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">Neutropenic Enterocolitis</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Embryofetal Toxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue
Injury</a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6  ADVERSE REACTIONS </span></a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials
Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7  DRUG INTERACTIONS </span></a></h1>
<h2><a href="#section-7.1" class="toc">7.1 G-CSF</a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8  USE IN SPECIFIC POPULATIONS 
</span></a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Lactation</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Females and Males of
Reproductive Potential</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10  OVERDOSAGE 
</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11  DESCRIPTION 
</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12  CLINICAL PHARMACOLOGY 
</span></a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13  NONCLINICAL TOXICOLOGY 
</span></a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14  CLINICAL STUDIES 
</span></a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Ovarian Cancer</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Small Cell Lung Cancer</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Cervical Cancer</a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">15  REFERENCES 
</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING
</span></a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc"><span class="Bold">17  PATIENT COUNSELING INFORMATION 
</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_130683f8-da0a-40c8-8777-e917c554fadb"></a><a name="section-1"></a><p></p>
<h1><span class="Bold"> WARNING: BONE MARROW SUPPRESSION 
</span></h1>
<p class="First"><span class="Bold">Topotecan hydrochloride </span><span class="Bold">can cause severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Administer only to patients with baseline neutrophil counts of greater than or equal to 1,500 cells/mm<span class="Sup">3</span> and platelet counts greater than or equal to 100,000 cells/mm<span class="Sup">3</span>. Monitor blood cell counts <span class="Italics">[see <a href="#LINK_20e21abb-c512-489c-bc9b-95fe02451696">Warnings and Precautions (5.1)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_f1b6135c-a5e0-479c-b817-d0c59f61996e"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1  INDICATIONS AND USAGE 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bfd113e9-0659-4f48-b274-ff77df4fa430"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Ovarian Cancer

<span class="Bold">​</span>
</h2>
<p class="First">Topotecan Hydrochloride for Injection, as a single agent, is indicated for the treatment of patients with metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_44eb6e57-e6a7-4960-99c9-546ed4954357"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Small Cell Lung Cancer</h2>
<p class="First">Topotecan Hydrochloride for Injection, as a single agent, is indicated for the treatment of patients with small cell lung cancer with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d376f9c7-c134-4c4e-a130-af6e383f78bb"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Cervical Cancer</h2>
<p class="First">Topotecan Hydrochloride for Injection in combination with cisplatin is indicated for the treatment of patients with Stage IV-B, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_f2440372-e3e0-4a3f-96f0-8ed545f1b05b"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Verify dose using body surface area prior to dispensing. Recommended dosage should generally not exceed 4 mg intravenously <span class="Italics">[see <a href="#LINK_a040256a-69d4-4158-b7f4-4264d70b47cd">Overdosage (10)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ee81b4f7-236f-473f-87d5-63f4135f911a"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Ovarian Cancer</h2>
<p class="First"><span class="Underline">Recommended Dose and Schedule</span></p>
<p>The recommended dose of Topotecan Hydrochloride for Injection is 1.5 mg/m<span class="Sup">2</span> by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1411748f-e375-4bff-90a4-531b846025ed"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Small Cell Lung Cancer</h2>
<p class="First"><span class="Underline">Recommended Dose and Schedule</span></p>
<p>The recommended dose of Topotecan Hydrochloride for Injection is 1.5 mg/m<span class="Sup">2</span> by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5b2223d4-4c77-41ba-8cc1-3d21da037a31"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Cervical Cancer</h2>
<p class="First"><span class="Underline">Recommended Dose and Schedule</span></p>
<p>The recommended dose of Topotecan Hydrochloride for Injection is 0.75 mg/m<span class="Sup">2</span> by intravenous infusion over 30 minutes daily on Days 1, 2, and 3 in combination with cisplatin 50 mg/m<span class="Sup">2</span> on Day 1, repeated every 21 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d3839148-8041-40d0-ba5c-173ee2c8997e"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dose Modifications</h2>
<p class="First"><span class="Underline">Hematologic Toxicities</span></p>
<p><span class="Italics">For single-agent use, dose reduce Topotecan Hydrochloride for Injection to 1.25 mg/m<span class="Sup">2</span> for:</span></p>
<ul class="Disc">
<li>neutrophil counts of less than 500 cells/mm<span class="Sup">3</span>, or administer granulocyte-colony stimulating factor (G-CSF) starting no sooner than 24 hours following the last dose of Topotecan Hydrochloride for Injection.</li>
<li>platelet counts less than 25,000 cells/mm<span class="Sup">3</span> during previous cycle.</li>
</ul>
<p><span class="Italics">For combination use with cisplatin, dose reduce Topotecan Hydrochloride for Injection to 0.60 mg/m<span class="Sup">2</span> (and further to 0.45 mg/m<span class="Sup">2</span> if necessary) for:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (defined as neutrophil counts less than 1,000 cells/mm<span class="Sup">3</span> with temperature of greater than or equal to 38.0°C (100.4°F), or administer G-CSF starting no sooner than 24 hours following the last dose of Topotecan Hydrochloride for Injection.</li>
<li>platelet counts less than 25,000 cells/mm<span class="Sup">3</span> during previous cycle.</li>
</ul>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p><span class="Italics">For single-agent use, dose reduce Topotecan Hydrochloride for Injection</span> to 0.75 mg/m<span class="Sup">2</span> in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance [Clcr] = 20 to 39 mL/min). Insufficient data are available in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr less than 20 mL/min) to provide a dosage recommendation for Topotecan Hydrochloride for Injection<span class="Italics"> [see <a href="#LINK_472ae48f-4422-48b3-8eb6-a381d2a8ae28">Use in Specific Populations (8.6)</a>, <a href="#LINK_06a98ce8-ae26-4d62-b738-39eac62beee9">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ccaf4215-3365-4ca7-83f0-db597d2b2fc1"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Preparation and
Intravenous Administration</h2>
<p class="First">Topotecan Hydrochloride for Injection is a cytotoxic drug. Follow applicable special handling and disposable procedures.<span class="Sup">1</span></p>
<p><span class="Underline">Preparation and Administration</span></p>
<p>Reconstitute each 4-mg vial of Topotecan Hydrochloride for Injection with 4 mL Sterile Water for Injection, USP. Dilute the appropriate volume of the reconstituted solution in either 0.9% Sodium Chloride Intravenous Infusion, USP or 5% Dextrose in Water Injection, USP prior to administration.</p>
<p><span class="Underline">Stability</span></p>
<p>Unopened vials of Topotecan Hydrochloride for Injection are stable until the date indicated on the package when stored between 20°C and 25°C (68°F and 77°F) [see USP] and protected from light in the original carton. Because the vials contain no preservative, contents should be used immediately after reconstitution.</p>
<p>Reconstituted vials of Topotecan Hydrochloride for Injection diluted for infusion are stable at approximately 20°C to 25°C (68°F to 77°F) and ambient lighting conditions for 24 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_36ea209c-740f-4f89-b0b9-68929350564b"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3  DOSAGE FORMS AND STRENGTHS 
</span></h1>
<p class="First">For injection: 4 mg (topotecan free base) lyophilized powder in single-dose vial for reconstitution; light yellow to greenish powder.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_c1882ccd-7e14-4d4d-bd57-138b2a4eda4a"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4  CONTRAINDICATIONS 
</span></h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">To</span><span class="XmChange" style="border-left:1px solid;"><span class="XmChange">potecan</span> hydrochloride is contraindicated in patients who have a history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to topotecan.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_2c16711b-3345-4460-ae32-18fa3bdc6c01"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5  WARNINGS AND PRECAUTIONS 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_20e21abb-c512-489c-bc9b-95fe02451696"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Bone Marrow Suppression</h2>
<p class="First">Bone marrow suppression (primarily <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>) is the dose-limiting toxicity of topotecan hydrochloride. <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> is not cumulative over time. Severe myelotoxicity has been reported when topotecan hydrochloride is used in combination with cisplatin <span class="Italics">[see <a href="#LINK_fa555614-b55c-4c26-bafa-ff55a1fdb777">Drug Interactions (7)</a>]</span>.</p>
<ul class="Disc"><li>The following data on <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> are based on an integrated safety database from 8 trials (N = 879) using topotecan hydrochloride injection at 1.5 mg/m<span class="Sup">2</span> by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course in patients with ovarian cancer and small cell lung cancer and from one trial in patients with cervical cancer (N = 147) using topotecan hydrochloride 0.75 mg/m<span class="Sup">2</span> by intravenous infusion over 30 minutes daily on Days 1, 2, and 3 repeated every 21 days in combination with cisplatin 50 mg/m<span class="Sup">2</span> on Day 1.</li></ul>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></p>
<ul class="Disc">
<li>Monotherapy: Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (less than 500 cells/mm<span class="Sup">3</span>) occurred in 78% of patients, with a median duration of 7 days and was most common during Course 1 of treatment (58% of patients). Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> associated with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> occurred in 13% of patients and <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> occurred in 5% of patients. <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> occurred in 4% of patients and was fatal in 1% of patients. <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span> has been reported.</li>
<li>Combination with cisplatin: Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occurred in 48% of patients.</li>
</ul>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></p>
<ul class="Disc">
<li>Monotherapy: Grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (less than 25,000/mm<span class="Sup">3</span>) occurred in 27% of patients, with a median duration of 5 days.</li>
<li>Combination with cisplatin: Grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> occurred in 7% of patients. </li>
</ul>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></p>
<ul class="Disc">
<li>Monotherapy: Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (less than 8 g/dL) occurred in 37% of patients.</li>
<li>Combination with cisplatin: Grade 3 or Grade 4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occurred in 40% of patients. </li>
</ul>
<p>Administer topotecan hydrochloride only to patients with a baseline neutrophil count of greater than or equal to 1,500 cells/mm<span class="Sup">3</span> and a platelet count greater than or equal to 100,000/mm<span class="Sup">3</span>. Monitor peripheral blood counts frequently during treatment with topotecan hydrochloride. Refer to Section 2.4 for dose modification guidelines for hematological toxicities in subsequent courses. Do not treat patients with subsequent courses of topotecan hydrochloride until <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> recover to greater than 1,000 cells/mm<span class="Sup">3</span>, platelets recover to greater than 100,000 cells/mm<span class="Sup">3</span>, and hemoglobin levels recover to 9.0 g/dL (with transfusion if necessary).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f5f6744b-b23c-4a70-8004-d2c2ff20ff2a"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">Neutropenic Enterocolitis</span></h2>
<p class="First">Topotecan can cause fatal <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">typhlitis</span> (<span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">neutropenic enterocolitis</span>). Consider the possibility of <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">typhlitis</span> in patients presenting with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e5f4ecba-3f6d-41c8-8f53-789b80897646"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span> (ILD), including fatalities, has occurred with topotecan hydrochloride. Underlying risk factors include history of ILD, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, lung cancer, thoracic radiation, and use of pneumotoxic drugs and/or colony stimulating factors. Monitor patients for pulmonary symptoms indicative of ILD (e.g., <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>), and discontinue topotecan hydrochloride if a new diagnosis of ILD is confirmed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cfb4674a-20f9-4bbf-b29c-0a5a22fa13be"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Embryofetal Toxicity</h2>
<p class="First">Based on animal data, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. Topotecan caused embryolethality, fetotoxicity, and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats and rabbits when administered during organogenesis. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose of topotecan hydrochloride. Advise women of the potential risk to a fetus <span class="Italics">[see <a href="#LINK_a46c1483-2803-41b1-8494-ffdf17738e9b">Use in Specific Populations (8.1</a>, <a href="#LINK_7a632878-0c0d-4590-9ec2-230389fd6bc0">8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5d7af648-a58d-4392-a546-13309d9f1c0f"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue
Injury</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> with topotecan hydrochloride has been observed; severe cases have been reported. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occur, immediately stop administration of topotecan hydrochloride and institute recommended management procedures <span class="Italics">[see <a href="#LINK_21c0c221-9a4c-43f6-991a-7fdc5b2e922c">Adverse Reactions (6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_21c0c221-9a4c-43f6-991a-7fdc5b2e922c"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6  ADVERSE REACTIONS </span></h1>
<p class="First">The following serious adverse reactions are described below and elsewhere in the labeling:</p>
<ul class="Disc">
<li>Bone Marrow Suppression <span class="Italics">[see <a href="#LINK_20e21abb-c512-489c-bc9b-95fe02451696">Warnings and Precautions (5.1)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">Neutropenic Enterocolitis</span> <span class="Italics">[see <a href="#LINK_f5f6744b-b23c-4a70-8004-d2c2ff20ff2a">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Lung Disease</span> <span class="Italics">[see W<a href="#LINK_e5f4ecba-3f6d-41c8-8f53-789b80897646">arnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue Injury <span class="Italics">[see <a href="#LINK_5d7af648-a58d-4392-a546-13309d9f1c0f">Warnings and Precautions (5.5)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0a319ebb-e955-49ba-a475-6321c840af8d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials
Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold"><span class="Underline">Ovarian Cancer</span></span></p>
<p>Table 1 shows the Grade 3/4 hematologic and major non-hematologic adverse reactions in the topotecan/paclitaxel comparator trial in ovarian cancer.</p>
<table cellpadding="0" cellspacing="0" width="650px">
<caption><span>Table 1. Adverse Reactions Experienced by Greater Than or Equal To 5% of Ovarian Cancer Patients Randomized to Receive Topotecan Hydrochloride or Paclitaxel</span></caption>
<col width="1px">
<col width="1px">
<col width="1px">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Topotecan Hydrochloride</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold"><br> Paclitaxel</span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 112)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(n = 114)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Hematologic Grade 3/4</span></p></td>
<td align="center"><p class="First">%</p></td>
<td align="center"><p class="First">%</p></td>
</tr>
<tr>
<td><p class="First">Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (&lt;500 cells/mm<span class="Sup">3</span>)</p></td>
<td align="center"><p class="First">80</p></td>
<td align="center"><p class="First">21</p></td>
</tr>
<tr>
<td><p class="First">Grade 3/4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (Hgb &lt;8 g/dL)</p></td>
<td align="center"><p class="First">41</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First">Grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (&lt;25,000 plts/mm<span class="Sup">3</span>)</p></td>
<td align="center"><p class="First">27</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></p></td>
<td align="center"><p class="First">23</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Non-hematologic Grade 3/4</span></p></td>
<td align="center"><p class="First">%</p></td>
<td align="center"><p class="First">%</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></p></td>
<td align="center"></td>
<td></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span><span class="Sup">a</span></p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal obstruction</span></p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">2</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center"><p class="First">10</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">General disorders and administrative site conditions</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">7</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><span class="Sup">b</span></p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr><td class="Toprule" colspan="3"><p class="First"><span class="Sup">a</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> related to <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> occurred in 2% of patients receiving topotecan hydrochloride and 0% of patients receiving paclitaxel.</p></td></tr>
<tr class="Last"><td colspan="3"><p class="First"><span class="Sup">b</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> includes body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>, and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>.</p></td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline">Small Cell Lung Cancer</span></span></p>
<p>Table 2 shows the Grade 3/4 hematologic and major non-hematologic adverse reactions in the topotecan/CAV (cyclophosphamide-doxorubicin-vincristine) comparator trial in small cell lung cancer.</p>
<table cellpadding="0" cellspacing="0" width="650px">
<caption><span>Table 2. Adverse Reactions Experienced by Greater Than or Equal To 5% of Small Cell Lung Cancer Patients Randomized to Receive Topotecan Hydrochloride or CAV</span></caption>
<col width="1px">
<col width="1px">
<col width="1px">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Topotecan Hydrochloride</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold"> CAV</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 107)</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 104)</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First"><span class="Bold">Hematologic Grade 3/4</span></p></td>
<td class="Toprule" align="center"><p class="First">%</p></td>
<td class="Toprule" align="center"><p class="First">%</p></td>
</tr>
<tr>
<td><p class="First">Grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> (&lt;500 cells/mm<span class="Sup">3</span>)</p></td>
<td align="center"><p class="First">70</p></td>
<td align="center"><p class="First">72</p></td>
</tr>
<tr>
<td><p class="First">Grade 3/4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> (Hgb &lt;8 g/dL)</p></td>
<td align="center"><p class="First">42</p></td>
<td align="center"><p class="First">20</p></td>
</tr>
<tr>
<td><p class="First">Grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> (&lt;25,000 plts/mm<span class="Sup">3</span>)</p></td>
<td align="center"><p class="First">29</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></p></td>
<td align="center"><p class="First">28</p></td>
<td align="center"><p class="First">26</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Non-hematologic Grade 3/4</span></p></td>
<td align="center"><p class="First">%</p></td>
<td align="center"><p class="First">%</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span><span class="Sup">a</span></p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">5</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="center"><p class="First">9</p></td>
<td align="center"><p class="First">14</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">4</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center"><p class="First">8</p></td>
<td align="center"><p class="First">6</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">General disorders and administrative site conditions</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">10</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="center"><p class="First">9</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><span class="Sup">b</span></p></td>
<td align="center"><p class="First">5</p></td>
<td align="center"><p class="First">7</p></td>
</tr>
<tr><td class="Toprule" colspan="3"><p class="First"><span class="Sup">a</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> related to <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> occurred in 3% of patients receiving topotecan hydrochloride and 1% of patients receiving CAV.</p></td></tr>
<tr class="Last"><td colspan="3"><p class="First"><span class="Sup">b</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> includes body <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>, and <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>.</p></td></tr>
</tbody>
</table>
<p><span class="Italics">Hepatobiliary Disorders in Ovarian and Small Cell Lung Cancer Patients Receiving Topotecan Hydrochloride:</span> Based on the combined experience of 453 patients with metastatic ovarian carcinoma, and 426 patients with small cell lung cancer treated with topotecan hydrochloride, Grade 1 transient elevations in hepatic enzymes occurred in 8% of patients. Grade 3/4 elevations occurred in 4%. Grade 3/4 elevated bilirubin occurred in less than 2% of patients.</p>
<p><span class="Bold"><span class="Underline">Cervical Cancer</span></span></p>
<p>In the comparative trial with topotecan hydrochloride plus cisplatin versus cisplatin in patients with cervical cancer, the most common dose-limiting adverse reaction was <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Table 3 shows the hematologic and non-hematologic adverse reactions in patients with cervical cancer.</p>
<table cellpadding="0" cellspacing="0" width="650px">
<caption><span>Table 3. Adverse Reactions Experienced by Greater Than or Equal To 5% of Patients with Cervical Cancer Randomized to Receive Topotecan Hydrochloride plus Cisplatin or Cisplatin Monotherapy (Between- Arm Difference Greater Than or Equal To 2%)a</span></caption>
<col width="1px">
<col width="1px">
<col width="1px">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Topotecan Hydrochloride</span></p></td>
<td class="Toprule"></td>
</tr>
<tr>
<td></td>
<td align="center"><p class="First"><span class="Bold">plus Cisplatin</span></p></td>
<td align="center"><p class="First"><span class="Bold">Cisplatin</span></p></td>
</tr>
<tr>
<td></td>
<td align="center"><p class="First"><span class="Bold">(n = 140)</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 144)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td align="center"><p class="First"><span class="Bold">%</span></p></td>
<td align="center"><p class="First"><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First"><span class="Bold">Hematologic</span></p></td>
<td class="Toprule" align="center"></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> Grade 3 (&lt;1,000 to 500 cells/mm<span class="Sup">3</span>) </p></td>
<td align="center"><p class="First">26</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"> Grade 4 (&lt;500 cells/mm<span class="Sup">3</span>)</p></td>
<td align="center"><p class="First">48</p></td>
<td align="center"><p class="First">1</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> Grade 3 (Hgb &lt;8 to 6.5 g/dL) </p></td>
<td align="center"><p class="First">34</p></td>
<td align="center"><p class="First">19</p></td>
</tr>
<tr>
<td><p class="First"> Grade 4 (Hgb &lt;6.5 g/dL)</p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> Grade 3 (&lt;50,000 to 10,000 cells/mm<span class="Sup">3</span>) </p></td>
<td align="center"><p class="First">26</p></td>
<td align="center"><p class="First">3</p></td>
</tr>
<tr>
<td><p class="First"> Grade 4 (&lt;10,000 cells/mm<span class="Sup">3</span>)</p></td>
<td align="center"><p class="First">7</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Non-hematologic<span class="Sup">b,c</span></span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">General disorders and administrative site conditions </span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> Constitutional<span class="Sup">d </span></p></td>
<td align="center"><p class="First">69</p></td>
<td align="center"><p class="First">62</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><span class="Sup">e</span></p></td>
<td align="center"><p class="First">59</p></td>
<td align="center"><p class="First">50</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center"><p class="First">40</p></td>
<td align="center"><p class="First">37</p></td>
</tr>
<tr>
<td><p class="First"> <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>-<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></p></td>
<td align="center"><p class="First">6</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"> Other</p></td>
<td align="center"><p class="First">63</p></td>
<td align="center"><p class="First">56</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Dermatology<span class="Sup">f</span></span></p></td>
<td align="center"><p class="First">48</p></td>
<td align="center"><p class="First">20</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>-<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span><span class="Sup">f</span></span></p></td>
<td align="center"><p class="First">28</p></td>
<td align="center"><p class="First">18</p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Cardiovascular<span class="Sup">f</span></span></p></td>
<td align="center"><p class="First">25</p></td>
<td align="center"><p class="First">15</p></td>
</tr>
<tr><td class="Toprule" colspan="3"><p class="First"><span class="Sup">a</span> Includes patients who were eligible and treated.</p></td></tr>
<tr><td colspan="3"><p class="First"><span class="Sup">b</span> Data were collected using NCI Common Toxicity Criteria, v. 2.0.</p></td></tr>
<tr><td colspan="3"><p class="First"><span class="Sup">c</span> Grades 1 through 4 only. There were 3 patients who experienced <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> with investigator-designated attribution. The first patient experienced a Grade 5 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> in which the drug-related <span class="product-label-link" type="condition" conceptid="441264" conceptname="Primary thrombocytopenia">thrombocytopenia aggravated</span> the event. A second patient experienced <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> which were not treatment-related but probably aggravated by treatment. A third patient experienced a <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>; the latter was indirectly treatment-related.</p></td></tr>
<tr><td colspan="3"><p class="First"><span class="Sup">d</span> Constitutional includes <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (in the absence of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or loss.</p></td></tr>
<tr><td colspan="3"><p class="First"><span class="Sup">e</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> includes <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or cramping, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (non-cardiac and non-pleuritic), <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4009394" conceptname="Liver pain">hepatic pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuropathic pain</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> due to radiation, <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="4330445" conceptname="Pleuritic pain">pleuritic pain</span>, rectal or perirectal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and tumor <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p></td></tr>
<tr class="Last"><td colspan="3"><p class="First"><span class="Sup">f</span> High-level terms were included if the between-arm difference was ≥10%.</p></td></tr>
</tbody>
</table>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_63c66c57-c432-4747-8171-e16c287b35b0"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following reactions have been identified during postmarketing use of topotecan hydrochloride. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to topotecan hydrochloride.</p>
<p><span class="Underline">Blood and Lymphatic System Disorders</span></p>
<p>Severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (in association with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) <span class="Italics">[see <a href="#LINK_20e21abb-c512-489c-bc9b-95fe02451696">Warnings and Precautions (5.1)</a>]</span>. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></p>
<p>Allergic manifestations, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> potentially associated with <span class="product-label-link" type="condition" conceptid="4342664" conceptname="Neutropenic colitis">neutropenic enterocolitis</span> <span class="Italics">[see <a href="#LINK_f5f6744b-b23c-4a70-8004-d2c2ff20ff2a">Warnings and Precautions (5.2)</a>]</span>. </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">Pulmonary Disorders</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial lung disease</span> <span class="Italics">[see <a href="#LINK_e5f4ecba-3f6d-41c8-8f53-789b80897646">Warnings and Precautions (5.3)</a>]</span>.</p>
<p><span class="Underline">Skin and Subcutaneous Tissue Disorders </span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, severe <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, severe <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. </p>
<p><span class="Underline">General Disorders and Administration Site Conditions </span></p>
<p><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> <span class="Italics">[see <a href="#LINK_5d7af648-a58d-4392-a546-13309d9f1c0f">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_fa555614-b55c-4c26-bafa-ff55a1fdb777"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7  DRUG INTERACTIONS </span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_18d1082f-316d-4d81-8016-db110bee955e"></a><a name="section-7.1"></a><p></p>
<h2>7.1 G-CSF</h2>
<p class="First">Concomitant administration with G-CSF can prolong the duration of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. If G-CSF is used, it should be started no sooner than 24 hours following the last dose of topotecan hydrochloride.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_1d8180a9-90eb-46a8-a57b-3774963be528"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8  USE IN SPECIFIC POPULATIONS 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a46c1483-2803-41b1-8494-ffdf17738e9b"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>Based on animal data, topotecan hydrochloride can cause fetal harm when administered to a pregnant woman. Topotecan caused embryolethality, fetotoxicity, and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats and rabbits when administered during organogenesis at doses similar to the clinical dose <span class="Italics">[see Data]</span>. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. The background risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> for the indicated populations are unknown; however, the background risk in the US general population of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2% to 4% and of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span> is 15% to 20% of clinically recognized pregnancies.</p>
<p><span class="Underline">Data</span></p>
<p><span class="Italics">Animal Data:</span> In rabbits, a dose of 0.10 mg/kg/day (about equal to the clinical dose on a mg/m<span class="Sup">2</span> basis) given on Days 6 through 20 of gestation caused maternal toxicity, embryolethality, and reduced fetal body weight. In the rat, a dose of 0.23 mg/kg/day (about equal to the clinical dose on a mg/m<span class="Sup">2</span> basis) given for 14 days before mating through gestation Day 6 caused fetal resorption, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, pre-implant loss, and mild maternal toxicity. Administration of an intravenous dose of 0.10 mg/kg/day (about half the clinical dose on a mg/m<span class="Sup">2</span> basis) given to rats on Days 6 through 17 of gestation caused an increase in post-implantation mortality. This dose also caused an increase in total <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. The most frequent malformations were of the eye (<span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, rosette formation of the retina, coloboma of the retina, ectopic orbit), brain (dilated lateral and third ventricles), skull, and vertebrae.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bdb06d87-53fd-4b79-8a37-749e9d7efd64"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Lactation</h2>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>It is not known whether this drug is present in human milk; however, topotecan is excreted in rat milk at high concentrations <span class="Italics">[see Data]</span>. Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants with topotecan hydrochloride, advise nursing mothers to discontinue breastfeeding during treatment with topotecan hydrochloride.</p>
<p><span class="Underline">Data</span></p>
<p><span class="Italics">Animal Data:</span> Following intravenous administration of topotecan to lactating rats at a dose of 4.72 mg/m<span class="Sup">2</span> (about twice the clinical dose on a mg/m<span class="Sup">2</span> basis), topotecan was excreted into milk at concentrations up to 48-fold higher than those in plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7a632878-0c0d-4590-9ec2-230389fd6bc0"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Females and Males of
Reproductive Potential</h2>
<p class="First"><span class="Underline">Contraception</span></p>
<p><span class="Italics">Females:</span> Advise female patients of reproductive potential to use effective contraception during treatment with topotecan hydrochloride and for one month after the last dose. Advise females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking topotecan hydrochloride <span class="Italics">[see <a href="#LINK_a46c1483-2803-41b1-8494-ffdf17738e9b">Use in Specific Populations (8.1)</a>]</span>.</p>
<p><span class="Italics">Males:</span> Topotecan hydrochloride may damage spermatozoa, resulting in possible genetic and fetal abnormalities. Advise males with a female sexual partner of reproductive potential to use effective contraception during and for three months after treatment with topotecan hydrochloride <span class="Italics">[see <a href="#LINK_8f7ac55f-a37d-452b-9673-ced6b44b0fef">Nonclinical Toxicology (13.1)</a>]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p><span class="Italics">Females:</span> Topotecan hydrochloride may have both acute and long-term effects on fertility <span class="Italics">[see <a href="#LINK_8f7ac55f-a37d-452b-9673-ced6b44b0fef">Nonclinical Toxicology (13.1)</a>]</span>.</p>
<p><span class="Italics">Males:</span> Effects on spermatogenesis have been observed in animals administered topotecan hydrochloride. Advise males of the potential risk for impaired fertility and to seek counseling on fertility and family planning options prior to starting treatment <span class="Italics">[see <a href="#LINK_8f7ac55f-a37d-452b-9673-ced6b44b0fef">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5acc76d4-25e9-4add-b399-32df0a5303e5"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46a9e6c0-a0d2-49c5-9e43-996a51925d05"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 879 patients with metastatic ovarian cancer or small cell lung cancer in clinical trials of topotecan hydrochloride, 32% (n = 281) were aged 65 years and older, while 3.8% (n = 33) were aged 75 years and older. Of the 140 patients with Stage IV-B, relapsed, or refractory cervical cancer in clinical trials of topotecan hydrochloride who received topotecan hydrochloride plus cisplatin in the randomized clinical trial, 6% (n = 9) were aged 65 years and older, while 3% (n = 4) were aged 75 years and older.</p>
<p>No overall differences in effectiveness or safety were observed between these patients and younger adult patients, and other reported clinical experience has not identified differences in responses between the elderly and younger adult patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_472ae48f-4422-48b3-8eb6-a381d2a8ae28"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The systemic exposure to both topotecan lactone and total topotecan increased in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr = 20 to 39 mL/min) compared with patients with normal renal function (Clcr greater than 60 mL/min). Reduce the dose of topotecan hydrochloride in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr = 20 to 39 mL/min). No dosage adjustment of topotecan hydrochloride is recommended for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr = 40 to 60 mL/min) <span class="Italics">[see <a href="#LINK_d3839148-8041-40d0-ba5c-173ee2c8997e">Dosage and Administration (2.4)</a>, <a href="#LINK_06a98ce8-ae26-4d62-b738-39eac62beee9">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Insufficient data are available in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr less than 20 mL/min) to provide a dosage recommendation for topotecan hydrochloride.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_a040256a-69d4-4158-b7f4-4264d70b47cd"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">10  OVERDOSAGE 
</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> (up to 10-fold of the prescribed dose) occurred in patients treated with intravenous topotecan. The primary complication of overdosage is bone marrow suppression. The observed signs and symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are consistent with the known adverse reactions associated with topotecan hydrochloride for intravenous use <span class="Italics">[see <a href="#LINK_0a319ebb-e955-49ba-a475-6321c840af8d">Adverse Reactions (6.1</a>, <a href="#LINK_63c66c57-c432-4747-8171-e16c287b35b0">6.2)</a>]</span>. In addition, elevated hepatic enzymes and <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> have been reported following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. One patient received a single dose of 40 mg/m<span class="Sup">2</span> of intravenous topotecan and developed <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>, skin toxicity, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> leading to <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>. Another patient received a single dose of 35 mg/m<span class="Sup">2</span> and experienced severe, reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p>There is no known antidote for overdosage with topotecan hydrochloride. If an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is suspected, monitor the patient closely for bone marrow suppression and institute supportive-care measures (such as the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of G-CSF and antibiotic therapy) as appropriate.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_108ef8e5-efc4-46bb-bddf-812fcb73cae9"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">11  DESCRIPTION 
</span></h1>
<p class="First">Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitory activity. The chemical name for topotecan hydrochloride is (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1<span class="Italics">H</span>-pyrano[3’,4’:6,7] indolizino [1,2-<span class="Italics">b</span>]quinoline-3,14-(4<span class="Italics">H</span>,12<span class="Italics">H</span>)-dione monohydrochloride. It has the molecular formula C<span class="Sub">23</span>H<span class="Sub">23</span>N<span class="Sub">3</span>O<span class="Sub">5</span>•HCl and a molecular weight of 457.9. It is soluble in water and melts with decomposition at 213°C to 218°C.</p>
<p>Topotecan hydrochloride has the following structural formula:</p>
<p><img alt="1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=996430c0-ee26-4ed9-82b8-a8b645becba6&amp;name=topotecan-hcl-for-injection-1.jpg"> </p>
<p>Topotecan Hydrochloride for Injection is supplied as a sterile, lyophilized, buffered, light yellow to greenish powder available in single-dose vials. Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. The reconstituted solution ranges in color from yellow to yellow-green and is intended for administration by intravenous infusion.</p>
<p>Inactive ingredients are mannitol, 48 mg, and tartaric acid, 20 mg. Hydrochloric acid and sodium hydroxide may be used to adjust the pH. The solution pH ranges from 2.5 to 3.5.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_bea98805-940d-43d7-8de5-4d238d8a9d51"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">12  CLINICAL PHARMACOLOGY 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ccdace58-854d-4cf6-aecd-b5ee4a0d7433"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Topoisomerase I relieves torsional <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> in DNA by inducing reversible single-strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these single-strand breaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repair these double-strand breaks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_06a98ce8-ae26-4d62-b738-39eac62beee9"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following administration of Topotecan Hydrochloride for Injection at doses of 0.5 to 1.5 mg/m<span class="Sup">2</span> administered as a 30-minute infusion to cancer patients, topotecan exhibited multiexponential pharmacokinetics with a terminal half-life of 2 to 3 hours. Total exposure (AUC) is approximately dose-proportional.</p>
<p><span class="Underline">Distribution</span></p>
<p>Binding of topotecan to plasma proteins is approximately 35%. </p>
<p><span class="Underline">Metabolism</span></p>
<p>Topotecan undergoes a reversible pH-dependent hydrolysis of its lactone moiety; it is the lactone form that is pharmacologically active. At pH less than or equal to 4, the lactone is exclusively present, whereas the ring-opened hydroxy-acid form predominates at physiologic pH. <span class="Italics">In vitro</span> studies in human liver microsomes indicate topotecan is metabolized to an N-demethylated metabolite. The mean metabolite:parent AUC ratio was about 3% for total topotecan and topotecan lactone following intravenous administration.</p>
<p><span class="Underline">Excretion</span></p>
<p>Renal clearance is the primary route of topotecan elimination.</p>
<p>In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance/excretion trial in 4 patients with <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, the overall recovery of total topotecan and its N-desmethyl metabolite in urine and feces over 9 days averaged 73.4% ± 2.3% of the administered intravenous dose. Mean values of 50.8% ± 2.9% as total topotecan and 3.1% ± 1.0% as N-desmethyl topotecan were excreted in the urine following intravenous administration. Fecal elimination of total topotecan accounted for 17.9% ± 3.6% while fecal elimination of N-desmethyl topotecan was 1.7% ± 0.6%. An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine.</p>
<p><span class="Underline">Specific Populations</span></p>
<p><span class="Italics">Gender:</span> Plasma clearance of topotecan lactone in male patients was approximately 24% higher than that in female patients, largely reflecting difference in body size.</p>
<p><span class="Italics">Age:</span> Population pharmacokinetic analysis in female patients did not identify age as a significant factor. Decreased renal clearance, which is common in the elderly, is a more important determinant of topotecan clearance <span class="Italics">[see <a href="#LINK_d3839148-8041-40d0-ba5c-173ee2c8997e">Dosage and Administration (2.4)</a>, <a href="#LINK_46a9e6c0-a0d2-49c5-9e43-996a51925d05">Use in Specific Populations (8.5)</a>]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> In patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr = 40 to 60 mL/min), plasma clearance of topotecan lactone was decreased by 33% compared with patients with normal renal function (Clcr greater than 60 mL/min). In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Clcr = 20 to 39 mL/min), plasma clearance of topotecan lactone was reduced by 65% compared with patients with normal renal function. Dosage adjustment is recommended for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. No dosage adjustment is required in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#LINK_d3839148-8041-40d0-ba5c-173ee2c8997e">Dosage and Administration (2.4)</a>, <a href="#LINK_472ae48f-4422-48b3-8eb6-a381d2a8ae28">Use in Specific Populations (8.6)</a>]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Plasma clearance of topotecan lactone in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> serum bilirubin levels between 1.7 and 15.0 mg/dL) was decreased by 33% compared with patients with normal hepatic function (serum bilirubin levels less than 1.7 mg/dL).</p>
<p><span class="Underline">Drug Interactions</span></p>
<p><span class="Italics">Effects of Topotecan on Drug-Metabolizing Enzymes: </span><span class="Italics">In vitro</span> inhibition studies using marker substrates for human P450 CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A, or CYP4A or dihydropyrimidine dehydrogenase indicate that the activities of these enzymes were not altered by topotecan.</p>
<p><span class="Italics">Cisplatin:</span> Administration of cisplatin (60 or 75 mg/m<span class="Sup">2</span> on Day 1) before topotecan (0.75 mg/m<span class="Sup">2</span>/day on Days 1 to 5) in 9 patients with ovarian cancer had no significant effect on the C<span class="Sub">max</span> and AUC of total topotecan.</p>
<p>Topotecan (0.3 mg/m<span class="Sup">2</span> intravenous daily on Days 2 to 6) had no effect on the pharmacokinetics of free platinum in 15 patients with ovarian cancer who were administered cisplatin 50 mg/m<span class="Sup">2</span> (n = 9) or 75 mg/m<span class="Sup">2</span> (n = 6) on Day 2 after paclitaxel 110 mg/m<span class="Sup">2</span> on Day 1. Topotecan (0.75 mg/m<span class="Sup">2</span> intravenous daily on Days 1 to 5) had no effect on dose-normalized (60 mg/m<span class="Sup">2</span>) C<span class="Sub">max</span> values of free platinum in 13 patients with ovarian cancer who were administered 60 mg/m<span class="Sup">2</span> (n = 10) or 75 mg/m<span class="Sup">2</span> (n = 3) cisplatin on Day 1.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_8681a77e-9ff6-4d85-89af-9fe9116c04e3"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">13  NONCLINICAL TOXICOLOGY 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8f7ac55f-a37d-452b-9673-ced6b44b0fef"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity testing of topotecan has not been performed. Topotecan is known to be genotoxic to mammalian cells and is a probable carcinogen. Topotecan was mutagenic to L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells and clastogenic to cultured human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with and without metabolic activation. It was also clastogenic to mouse bone marrow. Topotecan did not cause mutations in bacterial cells.</p>
<p>Topotecan given to female rats prior to mating at a dose of 1.4 mg/m<span class="Sup">2</span> intravenous (about equal to the clinical dose on a mg/m<span class="Sup">2</span> basis) caused <span class="product-label-link" type="condition" conceptid="4037500" conceptname="Superovulation">superovulation</span> possibly related to inhibition of follicular atresia. This dose given to pregnant female rats also caused increased pre-implantation loss. Studies in dogs given 0.4 mg/m<span class="Sup">2</span> intravenous (about 0.25 times the clinical dose on a mg/m<span class="Sup">2</span> basis) of topotecan daily for a month suggest that treatment may cause an increase in the incidence of multinucleated spermatogonial giant cells in the testes. Topotecan may impair fertility in women and men.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_f8cc3f4e-bfa7-4b4f-a52f-617b068596b8"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14  CLINICAL STUDIES 
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c7a81be1-9ce8-4e02-886c-0efb5a2c65d2"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Ovarian Cancer</h2>
<p class="First">Topotecan hydrochloride was studied in 2 clinical trials of 223 patients given topotecan with metastatic ovarian carcinoma. All patients had disease that had recurred on, or was unresponsive to, a platinum-containing regimen. Patients in these 2 trials received an initial dose of 1.5 mg/m<span class="Sup">2</span> given by intravenous infusion over 30 minutes for 5 consecutive days, starting on Day 1 of a 21-day course.</p>
<p>One trial was a randomized trial of 112 patients treated with topotecan hydrochloride (1.5 mg/m<span class="Sup">2</span>/day × 5 days starting on Day 1 of a 21-day course) and 114 patients treated with paclitaxel (175 mg/m<span class="Sup">2</span> over 3 hours on Day 1 of a 21-day course). All patients had recurrent ovarian cancer after a platinum-containing regimen or had not responded to at least 1 prior platinum-containing regimen. Patients who did not respond to the trial therapy, or who progressed, could be given the alternative treatment. The efficacy outcome measures were response rate, response duration, and time to progression.</p>
<p>The results of the trial did not show statistically significant improvements in response rates, response duration, time to progression, and overall survival as shown in Table 4.</p>
<table cellpadding="0" cellspacing="0" width="650px">
<caption><span>Table 4. Efficacy of Topotecan Hydrochloride versus Paclitaxel in Ovarian Cancer</span></caption>
<col width="1px">
<col width="1px">
<col width="1px">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Topotecan Hydrochloride</span></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold"> Paclitaxel</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Parameter</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 112)</span></p></td>
<td align="center" colspan="2"><p class="First"><span class="Bold">(n = 114)</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First">Overall response rate (95% CI) </p></td>
<td class="Toprule" align="center"><p class="First">21% (13% to 28%)</p></td>
<td class="Toprule" align="center" colspan="2"><p class="First">14% (8% to 20%)</p></td>
</tr>
<tr>
<td><p class="First">Complete response rate</p></td>
<td align="center"><p class="First">5%</p></td>
<td align="center" colspan="2"><p class="First">3%</p></td>
</tr>
<tr>
<td><p class="First">Partial response rate</p></td>
<td align="center"><p class="First">16%</p></td>
<td align="center" colspan="2"><p class="First">11%</p></td>
</tr>
<tr>
<td><p class="First">Response duration<span class="Sup">a</span> (months) </p></td>
<td align="center" colspan="3"></td>
</tr>
<tr>
<td><p class="First">Median (95% CI)</p></td>
<td align="center"><p class="First">6.0 (5.1 to 7.6)</p></td>
<td align="center" colspan="2"><p class="First">5.0 (3.7 to 7.8)</p></td>
</tr>
<tr>
<td><p class="First">Time to progression (months) </p></td>
<td align="center" colspan="3"></td>
</tr>
<tr>
<td><p class="First">Median (95% CI)</p></td>
<td align="center"><p class="First">4.4 (2.8 to 5.4)</p></td>
<td align="center" colspan="2"><p class="First">3.4 (2.7 to 4.2)</p></td>
</tr>
<tr>
<td><p class="First">HR (Topotecan Hydrochloride:paclitaxel) (95% CI)</p></td>
<td align="center" colspan="3"><p class="First">0.76 (0.57 to 1.02)</p></td>
</tr>
<tr>
<td><p class="First">Survival (months) </p></td>
<td align="center" colspan="3"></td>
</tr>
<tr>
<td><p class="First">Median (95% CI)</p></td>
<td align="center" colspan="2"><p class="First">14.5 (10.7 to 16.5)</p></td>
<td align="center"><p class="First">12.2 (9.7 to 15.8)</p></td>
</tr>
<tr>
<td><p class="First">HR (Topotecan Hydrochloride:paclitaxel) (95% CI)</p></td>
<td align="center" colspan="3"><p class="First">0.97 (0.71 to 1.34)</p></td>
</tr>
<tr><td class="Toprule" colspan="4"><p class="First">HR = hazard-ratio; CI = confidence interval.</p></td></tr>
<tr class="Last"><td colspan="4"><p class="First"><span class="Sup">a</span> The calculation for duration of response was based on the interval between first response and time to progression.</p></td></tr>
</tbody>
</table>
<p>The median time to response was 7.6 weeks (range: 3.1 to 21.7) with topotecan hydrochloride compared with 6.0 weeks (range: 2.4 to 18.1) with paclitaxel. In the crossover phase, 8 of 61 (13%) patients who received topotecan hydrochloride after paclitaxel had a partial response and 5 of 49 (10%) patients who received paclitaxel after topotecan hydrochloride had a response (2 complete responses).</p>
<p>Topotecan hydrochloride was active in ovarian cancer patients who had developed resistance to platinum-containing therapy, defined as <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> while on, or tumor relapse within 6 months after completion of, a platinum-containing regimen. One complete and 6 partial responses were seen in 60 patients, for a response rate of 12%. In the same trial, there were no complete responders and 4 partial responders on the paclitaxel arm, for a response rate of 7%.</p>
<p>Topotecan hydrochloride was also studied in an open-label, non-comparative trial in 111 patients with recurrent ovarian cancer after treatment with a platinum-containing regimen, or who had not responded to 1 prior platinum-containing regimen. The response rate was 14% (95% CI: 7% to 20%). The median duration of response was 22 weeks (range: 4.6 to 41.9 weeks). The time to progression was 11.3 weeks (range: 0.7 to 72.1 weeks). The median survival was 67.9 weeks (range: 1.4 to 112.9 weeks).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_703a8d88-02e8-4ace-834a-5dd2c51b85a2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Small Cell Lung Cancer</h2>
<p class="First">Topotecan hydrochloride was studied in 426 patients with recurrent or progressive small cell lung cancer in 1 randomized, comparative trial and in 3 single-arm trials. </p>
<p><span class="Underline">Randomized Comparative Trial</span></p>
<p>In a randomized, comparative, Phase 3 trial, 107 patients were treated with topotecan hydrochloride (1.5 mg/m<span class="Sup">2</span>/day × 5 days starting on Day 1 of a 21-day course) and 104 patients were treated with CAV (1,000 mg/m<span class="Sup">2</span> cyclophosphamide, 45 mg/m<span class="Sup">2</span> doxorubicin, 2 mg vincristine administered sequentially on Day 1 of a 21-day course). All patients were considered sensitive to first-line chemotherapy (responders who then subsequently progressed greater than or equal to 60 days after completion of first-line therapy). A total of 77% of patients treated with topotecan hydrochloride and 79% of patients treated with CAV received platinum/etoposide with or without other agents as first-line chemotherapy. The efficacy outcome measures were response rate and duration of response.</p>
<p>The results of the trial did not show statistically significant improvements in response rates, response duration, time to progression, and overall survival as shown in Table 5.</p>
<table cellpadding="0" cellspacing="0" width="650px">
<caption><span>Table 5. Efficacy of Topotecan Hydrochloride versus CAV (cyclophosphamide-doxorubicin-vincristine) in Small Cell Lung Cancer Patients Sensitive to First-Line Chemotherapy</span></caption>
<col width="1px">
<col width="1px">
<col width="1px">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Topotecan Hydrochloride</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold"> CAV</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Parameter</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 107)</span></p></td>
<td align="center"><p class="First"><span class="Bold">(n = 104)</span></p></td>
</tr>
<tr>
<td class="Toprule"><p class="First">Overall response rate (95% CI) </p></td>
<td class="Toprule" align="center"><p class="First">24% (16% to 32%)</p></td>
<td class="Toprule" align="center"><p class="First">18% (11% to 26%)</p></td>
</tr>
<tr>
<td><p class="First">Complete response rate</p></td>
<td align="center"><p class="First">0%</p></td>
<td align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td><p class="First">Partial response rate </p></td>
<td align="center"><p class="First">24%</p></td>
<td align="center"><p class="First">17%</p></td>
</tr>
<tr>
<td><p class="First">Response duration<span class="Sup">a</span> (months) </p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First">Median (95% CI)</p></td>
<td align="center"><p class="First">3.3 (3.0 to 4.1)</p></td>
<td align="center"><p class="First">3.5 (3.0 to 5.3)</p></td>
</tr>
<tr>
<td><p class="First">Time to progression (months) </p></td>
<td align="center" colspan="2"></td>
</tr>
<tr>
<td><p class="First">Median (95% CI)</p></td>
<td align="center"><p class="First">3.1 (2.6 to 4.1)</p></td>
<td align="center"><p class="First">2.8 (2.5 to 3.2)</p></td>
</tr>
<tr>
<td><p class="First">HR (Topotecan Hydrochloride:CAV) (95% CI)</p></td>
<td align="center" colspan="2"><p class="First">0.92 (0.69 to 1.22)</p></td>
</tr>
<tr>
<td><p class="First">Survival (months) </p></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td><p class="First">Median (95% CI)</p></td>
<td align="center"><p class="First">5.8 (4.7 to 6.8)</p></td>
<td align="center"><p class="First">5.7 (5.0 to 7.0)</p></td>
</tr>
<tr>
<td><p class="First">HR (Topotecan Hydrochloride:CAV) (95% CI)</p></td>
<td align="center" colspan="2"><p class="First">1.04 (0.78 to 1.39)</p></td>
</tr>
<tr><td class="Toprule" colspan="3"><p class="First">HR = hazard-ratio; CI = confidence interval.</p></td></tr>
<tr class="Last"><td colspan="3"><p class="First"><span class="Sup">a</span> The calculation for duration of response was based on the interval between first response and time to progression.</p></td></tr>
</tbody>
</table>
<p>The time to response was similar in both arms: topotecan hydrochloride median of 6 weeks (range: 2.4 to 15.7) versus CAV median 6 weeks (range: 5.1 to 18.1).</p>
<p>Changes on a disease-related symptom scale in patients who received topotecan hydrochloride or who received CAV are presented in Table 6. It should be noted that not all patients had all symptoms, nor did all patients respond to all questions. Each symptom was rated on a 4-category scale with an improvement defined as a change in 1 category from baseline sustained over 2 courses. Limitations in interpretation of the rating scale and responses preclude formal statistical analysis.</p>
<table cellpadding="0" cellspacing="0" width="650px">
<caption><span>Table 6. Percentage of Patients with Symptom Improvementa: Topotecan Hydrochloride versus CAV in Patients with Small Cell Lung Cancer</span></caption>
<col width="1px">
<col width="1px">
<col width="1px">
<col width="1px">
<col width="1px">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Topotecan Hydrochloride</span></p></td>
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">CAV</span></p></td>
</tr>
<tr>
<td></td>
<td align="center" colspan="2"><p class="First"><span class="Bold">(n = 107)</span></p></td>
<td align="center" colspan="2"><p class="First"><span class="Bold">(n = 104)</span></p></td>
</tr>
<tr>
<td class="Botrule"><p class="First"><span class="Bold">Symptom</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">n<span class="Sup">b</span></span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(%)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">n<span class="Sup">b</span></span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(%)</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> </p></td>
<td align="center"><p class="First">68</p></td>
<td align="center"><p class="First">(28)</p></td>
<td align="center"><p class="First">61</p></td>
<td align="center"><p class="First">(7)</p></td>
</tr>
<tr>
<td><p class="First">Interference with daily activity </p></td>
<td align="center"><p class="First">67</p></td>
<td align="center"><p class="First">(27)</p></td>
<td align="center"><p class="First">63</p></td>
<td align="center"><p class="First">(11)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">70</p></td>
<td align="center"><p class="First">(23)</p></td>
<td align="center"><p class="First">65</p></td>
<td align="center"><p class="First">(9)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">Hoarseness</span> </p></td>
<td align="center"><p class="First">40</p></td>
<td align="center"><p class="First">(33)</p></td>
<td align="center"><p class="First">38</p></td>
<td align="center"><p class="First">(13)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </p></td>
<td align="center"><p class="First">69</p></td>
<td align="center"><p class="First">(25)</p></td>
<td align="center"><p class="First">61</p></td>
<td align="center"><p class="First">(15)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td align="center"><p class="First">57</p></td>
<td align="center"><p class="First">(33)</p></td>
<td align="center"><p class="First">53</p></td>
<td align="center"><p class="First">(19)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </p></td>
<td align="center"><p class="First">56</p></td>
<td align="center"><p class="First">(32)</p></td>
<td align="center"><p class="First">57</p></td>
<td align="center"><p class="First">(16)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td align="center"><p class="First">44</p></td>
<td align="center"><p class="First">(25)</p></td>
<td align="center"><p class="First">41</p></td>
<td align="center"><p class="First">(17)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span></p></td>
<td align="center"><p class="First">15</p></td>
<td align="center"><p class="First">(27)</p></td>
<td align="center"><p class="First">12</p></td>
<td align="center"><p class="First">(33)</p></td>
</tr>
<tr><td class="Toprule" colspan="5"><p class="First"><span class="Sup">a</span> Defined as improvement sustained over at least 2 courses compared with baseline.</p></td></tr>
<tr class="Last"><td colspan="5"><p class="First"><span class="Sup">b</span> Number of patients with baseline and at least 1 post-baseline assessment.</p></td></tr>
</tbody>
</table>
<p><span class="Underline">Single-Arm Trials</span></p>
<p>Topotecan hydrochloride was also studied in 3 open-label, non-comparative trials in a total of 319 patients with recurrent or progressive small cell lung cancer after treatment with first-line chemotherapy. In all 3 trials, patients were stratified as either sensitive (responders who then subsequently progressed greater than or equal to 90 days after completion of first-line therapy) or refractory (no response to first-line chemotherapy or who responded to first-line therapy and then progressed within 90 days of completing first-line therapy). Response rates ranged from 11% to 31% for sensitive patients and 2% to 7% for refractory patients. Median time to progression and median survival were similar in all 3 trials and the comparative trial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ee6c206e-df13-4601-ae91-a31cf42809ab"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Cervical Cancer</h2>
<p class="First">In a comparative trial, 147 eligible women were randomized to topotecan hydrochloride (0.75 mg/m<span class="Sup">2</span>/day intravenous over 30 minutes × 3 consecutive days starting on Day 1 of a 21-day course) plus cisplatin (50 mg/m<span class="Sup">2</span> on Day 1) and 146 eligible women were randomized to cisplatin (50 mg/m<span class="Sup">2</span> intravenous on Day 1 of a 21-day course). All patients had histologically confirmed Stage IV-B, recurrent, or persistent carcinoma of the cervix considered not amenable to curative treatment with surgery and/or radiation. Fifty-six percent (56%) of patients treated with topotecan hydrochloride plus cisplatin and 56% of patients treated with cisplatin had received prior cisplatin with or without other agents as first-line chemotherapy.</p>
<p>Median survival of eligible patients receiving topotecan hydrochloride plus cisplatin was 9.4 months (95% CI: 7.9 to 11.9) compared with 6.5 months (95% CI: 5.8 to 8.8) among patients randomized to cisplatin alone with a log rank <span class="Italics">P</span>-value of 0.033 (significance level was 0.044 after adjusting for the interim analysis). The unadjusted hazard ratio for overall survival was 0.76 (95% CI: 0.59 to 0.98).</p>
<p><span class="Bold"><img alt="`" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=996430c0-ee26-4ed9-82b8-a8b645becba6&amp;name=topotecan-hcl-for-injection-2.jpg"><p class="MultiMediaCaptionNotCentered">Figure 1. Overall Survival Curves Comparing Topotecan Hydrochloride plus Cisplatin versus Cisplatin Monotherapy in Cervical Cancer Patients</p></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_42100b70-6ade-475d-b6ee-b500ffc27bda"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">15  REFERENCES 
</span></h1>
<ol class="Arabic"><li>?OSHA Hazardous Drugs.? <span class="Italics">OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html.</span>
</li></ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_00579d65-05ad-4318-86eb-8403deec027a"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">16  HOW SUPPLIED/STORAGE AND HANDLING
</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_18aa74a0-2451-4ae3-abbb-cda97f0fbc15"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Topotecan Hydrochloride for Injection is supplied in 4-mg (free base) single-dose vials.</p>
<p>4 mg Single-Dose Vial - NDC 45963-615-56 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7d93db80-b7a5-4af5-94f4-2ad7f9e664e9"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]</p>
<p>Protect from light in original carton. Handle and dispose of Topotecan Hydrochloride for Injection consistent with recommendations for the handling and disposal of hazardous drugs<span class="Sup">1</span>.</p>
<p><span class="Bold">Sterile, Nonpyrogenic, preservative-free.</span></p>
<p><span class="Bold">The container closure is not made with natural rubber latex.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_165de6bc-2171-4a3d-9fcd-bca3c8b29d0a"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">17  PATIENT COUNSELING INFORMATION 
</span></h1>
<ul class="Disk"><li>
<span class="Bold">Bone Marrow Suppression<br></span>Inform patients that Topotecan Hydrochloride for Injection decreases blood cell counts such as white blood cells, platelets, and red blood cells. Advise patients to notify their healthcare provider promptly for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, or burning <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on urination), or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Inform patients that frequent blood tests will be performed while taking Topotecan Hydrochloride for Injection to monitor for the occurrence of bone marrow suppression.</li></ul>
<ul class="Disk"><li>
<span class="Bold">Embryofetal Toxicity<br></span>Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected during treatment with Topotecan Hydrochloride for Injection. Advise females of reproductive potential to use effective contraception during treatment and for 1 month after the last dose of Topotecan Hydrochloride for Injection. Advise males with a female sexual partner of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of Topotecan Hydrochloride for Injection <span class="Italics">[see <a href="#LINK_cfb4674a-20f9-4bbf-b29c-0a5a22fa13be">Warnings and Precautions (5.4)</a>, <a href="#LINK_a46c1483-2803-41b1-8494-ffdf17738e9b">Use in Specific Populations (8.1</a>, <a href="#LINK_7a632878-0c0d-4590-9ec2-230389fd6bc0">8.3)</a>]</span>.</li></ul>
<ul class="Disk"><li>
<span class="Bold">Lactation<br></span>Advise nursing mothers to discontinue breastfeeding during treatment with Topotecan Hydrochloride for Injection <span class="Italics">[see <a href="#LINK_bdb06d87-53fd-4b79-8a37-749e9d7efd64">Use in Specific Populations (8.2)</a>]</span>.</li></ul>
<ul class="Disk"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span><br></span>Advise male and female patients of the potential risk for impaired fertility and possible family planning options <span class="Italics">[see <a href="#LINK_7a632878-0c0d-4590-9ec2-230389fd6bc0">Use in Specific Populations (8.3)</a>]</span>.</li></ul>
<ul class="Disk"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br></span>Advise patients that Topotecan Hydrochloride for Injection may cause <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. These symptoms may impair the ability to safely drive or operate machinery.</li></ul>
<p class="First">Manufactured by: <br>Sindan Pharma SRL<br>11 Ion Mihalache Blvd<br>Bucharest 1, Romania 011171</p>
<p>Distributed by:<br>Actavis Pharma, Inc.<br>Parsippany, NJ 07054 USA</p>
<p>Revised - July 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_65e65a18-9c1e-46c5-a81b-6b3dca772007"></a><a name="section-17"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<div class="Figure"><img alt="1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=996430c0-ee26-4ed9-82b8-a8b645becba6&amp;name=topotecan-hcl-for-injection-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOPOTECAN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">topotecan hydrochloride injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:45963-615</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOPOTECAN HYDROCHLORIDE</strong> (TOPOTECAN) </td>
<td class="formItem">TOPOTECAN</td>
<td class="formItem">4 mg  in 4 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:45963-615-56</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">4 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090620</td>
<td class="formItem">01/05/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Pharma, Inc.
							(119723554)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sindan-Pharma Srl</td>
<td class="formItem"></td>
<td class="formItem">683754121</td>
<td class="formItem">ANALYSIS(45963-615), LABEL(45963-615), MANUFACTURE(45963-615), PACK(45963-615)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8c7f05e6-ffbb-47b4-89dd-0e881e79a8db</div>
<div>Set id: 996430c0-ee26-4ed9-82b8-a8b645becba6</div>
<div>Version: 5</div>
<div>Effective Time: 20150731</div>
</div>
</div> <div class="DistributorName">Actavis Pharma, Inc.</div></p>
</body></html>
